| RadNet Announces 2010 First Quarter Financial Results Conference Call (GlobeNewswire) LOS ANGELES -- RadNet, Inc. , a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 188 fully-owned and operated outpatient imaging centers, today announced that Dr. us.rd.yahoo.com |
YM BioSciences Reshuffles the Cytopia Deck Bio Tuesday submits: YM BioSciences (YMI) got more than it bargained for with its recent acquisition of Australia’s Cytopia. CEO David Allan told BioTuesday.ca in an exclusive interview:When we were buying the company, our sole interest was in CYT997, Cytopia’s lead vascular disrupting agent (VDA).VDAs, which can disrupt the blood flow that feed tumours, became a hot target in 2007 after Britain’s Antisoma (ATSMY.PK) licensed its VDA to Novartis (NVS) in a deal valued at a total of nearly $1 billion (US dollars). Allan recalls:Complete Story » seekingalpha.com |
Colt McCoy teams up with Scott & White - Video Colt McCoy Teams with Scott & White to build Children’s Hospital feedproxy.google.com |
Avanir Traders Turn to Put Selling optionMONSTER submits: By Chris McKhann Options are active in Avanir Pharmaceuticals (AVNR) for a second straight session as traders seek to capitalize on the stock's volatility.Complete Story » seekingalpha.com |
Endo Pharmaceuticals Acquires Apax's Qualitest for $1.2B U.S.-based specialty healthcare company Endo Pharmaceuticals (NASDAQ:ENDP) has agreed to buy Qualitest Pharmaceuticals, the sixth largest generic pharmaceutical company in the U.S., for around $1.2 billion in cash from London-based buyout shop Apax Partners, it said Tuesday. Huntsville, Alabama-based Qualitest manufactures controlled substances from its facilities in the U.S., which make up approximately 40% of its product portfolio, with liquids making up the remaining 17% of its portfolio. Thirty-two of Qualitest's products are listed among the top 250 generics by total prescription (TRx) volume.Complete Story » seekingalpha.com |